Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial)

Schmid, Andrea; Friess, Dorothea; Mansouri Taleghani, Behrouz; Keller, Peter; Müller, Beatrice Ursula; Baerlocher, Gabriela M.; Leibundgut, Kurt; Pabst, Thomas (2014). Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leukemia & lymphoma, 56(3), pp. 608-614. Informa Healthcare 10.3109/10428194.2014.927454

[img] Text
GMB_BM_PAV-trial Leukemia and Lymphoma 2015.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.
Download (5MB) | Request a copy

Current practice in Switzerland for the mobilization of autologous stem cells in patients with myeloma is combining vinorelbine chemotherapy and granulocyte-colony stimulating factor (G-CSF) cytokine stimulation. We prospectively investigated adding intravenous plerixafor to the vinorelbine/G-CSF combination (VGP), and compared it with vinorelbine/plerixafor (VP) and G-CSF/plerixafor (GP) combinations. In a final cohort (VP-late), plerixafor was given on the first day of CD34 + cells increasing to > 15 000/mL peripheral blood. Four consecutive cohorts of 10 patients with myeloma were studied. We observed that intravenously administered plerixafor can be safely combined with vinorelbine/G-CSF. VGP was superior in mobilizing peripheral stem and progenitor cells compared to the three double combinations (VP, GP and VP-late), and GP mobilized better than VP. Our data indicate that the triple combination of VGP is an efficient strategy to collect autologous CD34 + cells, with G-CSF contributing predominantly in this concept. Plerixafor can be safely added to G-CSF and/or vinorelbine chemotherapy.

Item Type:

 Journal Article (Original Article)

Division/Institute:

 04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hämatologie / Onkologie (Pädiatrie)
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hämatologie / Onkologie (Pädiatrie)

UniBE Contributor:

 Friess, Dorothea, Mansouri Taleghani, Behrouz, Keller, Peter, Müller, Beatrice Ursula, Baerlocher, Gabriela M., Leibundgut, Kurt, Pabst, Thomas Niklaus

Subjects:

 600 Technology > 610 Medicine & health

ISSN:

 1042-8194

Publisher:

 Informa Healthcare

Language:

 English

Submitter:

 Anette van Dorland

Date Deposited:

 10 Feb 2015 16:37

Last Modified:

 02 Mar 2023 23:25

Publisher DOI:

 10.3109/10428194.2014.927454

PubMed ID:

 24884311

Uncontrolled Keywords:

 Clinical results, myeloma, stem cell mobilization

BORIS DOI:

 10.7892/boris.62871

URI:

 https://boris.unibe.ch/id/eprint/62871

Actions (login required)

Edit item Edit item
Provide Feedback